unknown
Stage
About
General Control Biotechnologies develops programmable epigenetic therapies that rewrite gene expression to healthy baselines, aiming to treat complex age-related diseases by using multiplexed, locus-specific epigenetic editors. Their platform is focused on coordinated control of multiple genes within a single therapy for indications like Alzheimer’s and sarcopenia.
Explore General Control Biotechnologies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.